The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.

Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ 3rd

Diabetes, obesity & metabolism19 Jan 2011Cited by 69 (Europe PMC)

PMID21251180DOI10.1111/j.1463-1326.2011.01366.xPepBankPUB-21251180

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, all LY doses significantly reduced fasting blood glucose compared with placebo.
In plain wordsIn patients with type 2 diabetes, all LY doses reduced fasting blood sugar more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFasting blood glucose
Study
n = 262
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg for 4 weeks then 1.0 mg for 12 weeks; 1.0 mg for 16 weeks; or 1.0 mg for 4 weeks then 2.0 mg for 12 weeks, once weekly · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Both fasting (p < 0.001) and postprandial (p < 0.05) blood glucose decreased significantly compared to placebo at all LY doses.
2 context sentences(design, population, supporting numbers)
Summary · context
Placebo-controlled, double-blind study in 262 patients (mean age 57 ± 12 years; BMI 33.9 ± 4.1 kg/m(2); and glycosylated haemoglobin A1c (A1c) 8.24 ± 0.93%) receiving two OAMs.
Summary · context
Patients were randomized to once-weekly subcutaneous injections of placebo or LY 0.5 mg for 4 weeks, then 1.0 mg for 12 weeks (LY 0.5/1.0); 1.0 mg for 16 weeks (LY 1.0/1.0); or 1.0 mg for 4 weeks, then 2.0 mg for 12 weeks (LY 1.0/2.0).
Report a problemFND-2125118004
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, all LY doses significantly reduced postprandial blood glucose compared with placebo.
In plain wordsIn patients with type 2 diabetes, all LY doses reduced blood sugar after meals more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePostprandial blood glucose
Study
n = 262
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg for 4 weeks then 1.0 mg for 12 weeks; 1.0 mg for 16 weeks; or 1.0 mg for 4 weeks then 2.0 mg for 12 weeks, once weekly · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Both fasting (p < 0.001) and postprandial (p < 0.05) blood glucose decreased significantly compared to placebo at all LY doses.
2 context sentences(design, population, supporting numbers)
Summary · context
Placebo-controlled, double-blind study in 262 patients (mean age 57 ± 12 years; BMI 33.9 ± 4.1 kg/m(2); and glycosylated haemoglobin A1c (A1c) 8.24 ± 0.93%) receiving two OAMs.
Summary · context
Patients were randomized to once-weekly subcutaneous injections of placebo or LY 0.5 mg for 4 weeks, then 1.0 mg for 12 weeks (LY 0.5/1.0); 1.0 mg for 16 weeks (LY 1.0/1.0); or 1.0 mg for 4 weeks, then 2.0 mg for 12 weeks (LY 1.0/2.0).
Report a problemFND-2125118005
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, LY produced dose-dependent weight losses of -1.34 to -2.55 kg, significantly greater than placebo.
In plain wordsIn patients with type 2 diabetes, LY reduced weight more than placebo, with losses that depended on dose.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight loss
Study
n = 262
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.5 mg for 4 weeks then 1.0 mg for 12 weeks; 1.0 mg for 16 weeks; or 1.0 mg for 4 weeks then 2.0 mg for 12 weeks, once weekly · subcutaneous · 16 weeksAs given in this study (human).
Measurements
Weight change
−1.34 to −2.55 kg
LY arms at 16 weeks
Source sentences
Summary
Weight loss was dose dependent and ranged from -1.34 ± 0.39 to -2.55 ± 0.40 kg at 16 weeks (all p < 0.05 vs. placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
Placebo-controlled, double-blind study in 262 patients (mean age 57 ± 12 years; BMI 33.9 ± 4.1 kg/m(2); and glycosylated haemoglobin A1c (A1c) 8.24 ± 0.93%) receiving two OAMs.
Summary · context
Patients were randomized to once-weekly subcutaneous injections of placebo or LY 0.5 mg for 4 weeks, then 1.0 mg for 12 weeks (LY 0.5/1.0); 1.0 mg for 16 weeks (LY 1.0/1.0); or 1.0 mg for 4 weeks, then 2.0 mg for 12 weeks (LY 1.0/2.0).
Report a problemFND-2125118006
04HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, hypoglycaemia was uncommon overall but more frequent with LY than placebo through the initial 4 weeks.
In plain wordsIn patients with type 2 diabetes, low blood sugar was uncommon but more frequent with LY than placebo during the initial 4 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHypoglycaemia
Study
n = 262
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.5 mg for 4 weeks then 1.0 mg for 12 weeks; 1.0 mg for 16 weeks; or 1.0 mg for 4 weeks then 2.0 mg for 12 weeks, once weekly · subcutaneous · initial 4 weeksAs given in this study (human).
Measurements
Hypoglycaemia rate
≤ 0.8 episodes/patient/30 days
overall
Source sentences
Summary
Hypoglycaemia was uncommon overall (≤0.8 episodes/patient/30 days) but more common with LY than placebo through the initial 4 weeks (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Placebo-controlled, double-blind study in 262 patients (mean age 57 ± 12 years; BMI 33.9 ± 4.1 kg/m(2); and glycosylated haemoglobin A1c (A1c) 8.24 ± 0.93%) receiving two OAMs.
Summary · context
Patients were randomized to once-weekly subcutaneous injections of placebo or LY 0.5 mg for 4 weeks, then 1.0 mg for 12 weeks (LY 0.5/1.0); 1.0 mg for 16 weeks (LY 1.0/1.0); or 1.0 mg for 4 weeks, then 2.0 mg for 12 weeks (LY 1.0/2.0).
Report a problemFND-2125118010
05HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, cardiovascular events did not differ between LY and placebo.
In plain wordsIn patients with type 2 diabetes, heart and blood vessel events did not differ between LY and placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeCardiovascular events
Study
n = 262
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
0.5 mg for 4 weeks then 1.0 mg for 12 weeks; 1.0 mg for 16 weeks; or 1.0 mg for 4 weeks then 2.0 mg for 12 weeks, once weekly · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
No differences in cardiovascular events or blood pressure were shown between treatments.
2 context sentences(design, population, supporting numbers)
Summary · context
Placebo-controlled, double-blind study in 262 patients (mean age 57 ± 12 years; BMI 33.9 ± 4.1 kg/m(2); and glycosylated haemoglobin A1c (A1c) 8.24 ± 0.93%) receiving two OAMs.
Summary · context
Patients were randomized to once-weekly subcutaneous injections of placebo or LY 0.5 mg for 4 weeks, then 1.0 mg for 12 weeks (LY 0.5/1.0); 1.0 mg for 16 weeks (LY 1.0/1.0); or 1.0 mg for 4 weeks, then 2.0 mg for 12 weeks (LY 1.0/2.0).
Report a problemFND-2125118011
06HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, blood pressure did not differ between LY and placebo.
In plain wordsIn patients with type 2 diabetes, blood pressure did not differ between LY and placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeBlood pressure
Study
n = 262
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.5 mg for 4 weeks then 1.0 mg for 12 weeks; 1.0 mg for 16 weeks; or 1.0 mg for 4 weeks then 2.0 mg for 12 weeks, once weekly · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
No differences in cardiovascular events or blood pressure were shown between treatments.
2 context sentences(design, population, supporting numbers)
Summary · context
Placebo-controlled, double-blind study in 262 patients (mean age 57 ± 12 years; BMI 33.9 ± 4.1 kg/m(2); and glycosylated haemoglobin A1c (A1c) 8.24 ± 0.93%) receiving two OAMs.
Summary · context
Patients were randomized to once-weekly subcutaneous injections of placebo or LY 0.5 mg for 4 weeks, then 1.0 mg for 12 weeks (LY 0.5/1.0); 1.0 mg for 16 weeks (LY 1.0/1.0); or 1.0 mg for 4 weeks, then 2.0 mg for 12 weeks (LY 1.0/2.0).
Report a problemFND-2125118012
07HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, LY 0.5/1.0 reduced A1c by 1.38% versus 0.24% with placebo.
In plain wordsIn patients with type 2 diabetes, LY 0.5/1.0 reduced long-term blood sugar more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseA1c change, LY 0.5/1.0
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg for 4 weeks then 1.0 mg for 12 weeks · subcutaneous · 16 weeksAs given in this study (human).
Measurements
A1c change
−1.38%
LY 0.5/1.0
A1c change
−0.24%
placebo
Source sentences
Summary
At week 16, A1c changes (least-squares mean ± standard error) were -0.24 ± 0.12, -1.38 ± 0.12, -1.32 ± 0.12 and -1.59 ± 0.12%, in the placebo, LY 0.5/1.0, LY 1.0/1.0 and LY 1.0/2.0 arms, respectively (all p < 0.001 vs. placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
Placebo-controlled, double-blind study in 262 patients (mean age 57 ± 12 years; BMI 33.9 ± 4.1 kg/m(2); and glycosylated haemoglobin A1c (A1c) 8.24 ± 0.93%) receiving two OAMs.
Summary · context
Patients were randomized to once-weekly subcutaneous injections of placebo or LY 0.5 mg for 4 weeks, then 1.0 mg for 12 weeks (LY 0.5/1.0); 1.0 mg for 16 weeks (LY 1.0/1.0); or 1.0 mg for 4 weeks, then 2.0 mg for 12 weeks (LY 1.0/2.0).
Report a problemFND-2125118001
08HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, LY 1.0/1.0 reduced A1c by 1.32% versus 0.24% with placebo.
In plain wordsIn patients with type 2 diabetes, LY 1.0/1.0 reduced long-term blood sugar more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseA1c change, LY 1.0/1.0
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · 16 weeksAs given in this study (human).
Measurements
A1c change
−1.32%
LY 1.0/1.0
A1c change
−0.24%
placebo
Source sentences
Summary
At week 16, A1c changes (least-squares mean ± standard error) were -0.24 ± 0.12, -1.38 ± 0.12, -1.32 ± 0.12 and -1.59 ± 0.12%, in the placebo, LY 0.5/1.0, LY 1.0/1.0 and LY 1.0/2.0 arms, respectively (all p < 0.001 vs. placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
Placebo-controlled, double-blind study in 262 patients (mean age 57 ± 12 years; BMI 33.9 ± 4.1 kg/m(2); and glycosylated haemoglobin A1c (A1c) 8.24 ± 0.93%) receiving two OAMs.
Summary · context
Patients were randomized to once-weekly subcutaneous injections of placebo or LY 0.5 mg for 4 weeks, then 1.0 mg for 12 weeks (LY 0.5/1.0); 1.0 mg for 16 weeks (LY 1.0/1.0); or 1.0 mg for 4 weeks, then 2.0 mg for 12 weeks (LY 1.0/2.0).
Report a problemFND-2125118002
09HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, LY 1.0/2.0 reduced A1c by 1.59% versus 0.24% with placebo.
In plain wordsIn patients with type 2 diabetes, LY 1.0/2.0 reduced long-term blood sugar more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseA1c change, LY 1.0/2.0
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg for 4 weeks then 2.0 mg for 12 weeks · subcutaneous · 16 weeksAs given in this study (human).
Measurements
A1c change
−1.59%
LY 1.0/2.0
A1c change
−0.24%
placebo
Source sentences
Summary
At week 16, A1c changes (least-squares mean ± standard error) were -0.24 ± 0.12, -1.38 ± 0.12, -1.32 ± 0.12 and -1.59 ± 0.12%, in the placebo, LY 0.5/1.0, LY 1.0/1.0 and LY 1.0/2.0 arms, respectively (all p < 0.001 vs. placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
Placebo-controlled, double-blind study in 262 patients (mean age 57 ± 12 years; BMI 33.9 ± 4.1 kg/m(2); and glycosylated haemoglobin A1c (A1c) 8.24 ± 0.93%) receiving two OAMs.
Summary · context
Patients were randomized to once-weekly subcutaneous injections of placebo or LY 0.5 mg for 4 weeks, then 1.0 mg for 12 weeks (LY 0.5/1.0); 1.0 mg for 16 weeks (LY 1.0/1.0); or 1.0 mg for 4 weeks, then 2.0 mg for 12 weeks (LY 1.0/2.0).
Report a problemFND-2125118003
10HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, nausea occurred in 13.8% at the highest LY dosage.
In plain wordsIn patients with type 2 diabetes, 13.8% had nausea at the highest LY dosage.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableNausea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.0 mg for 4 weeks then 2.0 mg for 12 weeks · subcutaneous · 16 weeksAs given in this study (human).
Measurements
Nausea
13.8%
highest LY dosage
Source sentences
Summary
At the highest LY dosage, the most common adverse events were nausea (13.8%), diarrhoea (13.8%) and abdominal distension (13.8%).
2 context sentences(design, population, supporting numbers)
Summary · context
Placebo-controlled, double-blind study in 262 patients (mean age 57 ± 12 years; BMI 33.9 ± 4.1 kg/m(2); and glycosylated haemoglobin A1c (A1c) 8.24 ± 0.93%) receiving two OAMs.
Summary · context
Patients were randomized to once-weekly subcutaneous injections of placebo or LY 0.5 mg for 4 weeks, then 1.0 mg for 12 weeks (LY 0.5/1.0); 1.0 mg for 16 weeks (LY 1.0/1.0); or 1.0 mg for 4 weeks, then 2.0 mg for 12 weeks (LY 1.0/2.0).
Report a problemFND-2125118007
11HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, diarrhoea occurred in 13.8% at the highest LY dosage.
In plain wordsIn patients with type 2 diabetes, 13.8% had diarrhoea at the highest LY dosage.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDiarrhoea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.0 mg for 4 weeks then 2.0 mg for 12 weeks · subcutaneous · 16 weeksAs given in this study (human).
Measurements
Diarrhoea
13.8%
highest LY dosage
Source sentences
Summary
At the highest LY dosage, the most common adverse events were nausea (13.8%), diarrhoea (13.8%) and abdominal distension (13.8%).
2 context sentences(design, population, supporting numbers)
Summary · context
Placebo-controlled, double-blind study in 262 patients (mean age 57 ± 12 years; BMI 33.9 ± 4.1 kg/m(2); and glycosylated haemoglobin A1c (A1c) 8.24 ± 0.93%) receiving two OAMs.
Summary · context
Patients were randomized to once-weekly subcutaneous injections of placebo or LY 0.5 mg for 4 weeks, then 1.0 mg for 12 weeks (LY 0.5/1.0); 1.0 mg for 16 weeks (LY 1.0/1.0); or 1.0 mg for 4 weeks, then 2.0 mg for 12 weeks (LY 1.0/2.0).
Report a problemFND-2125118008
12HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, abdominal distension occurred in 13.8% at the highest LY dosage.
In plain wordsIn patients with type 2 diabetes, 13.8% had abdominal swelling at the highest LY dosage.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableAbdominal distension
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.0 mg for 4 weeks then 2.0 mg for 12 weeks · subcutaneous · 16 weeksAs given in this study (human).
Measurements
Abdominal distension
13.8%
highest LY dosage
Source sentences
Summary
At the highest LY dosage, the most common adverse events were nausea (13.8%), diarrhoea (13.8%) and abdominal distension (13.8%).
2 context sentences(design, population, supporting numbers)
Summary · context
Placebo-controlled, double-blind study in 262 patients (mean age 57 ± 12 years; BMI 33.9 ± 4.1 kg/m(2); and glycosylated haemoglobin A1c (A1c) 8.24 ± 0.93%) receiving two OAMs.
Summary · context
Patients were randomized to once-weekly subcutaneous injections of placebo or LY 0.5 mg for 4 weeks, then 1.0 mg for 12 weeks (LY 0.5/1.0); 1.0 mg for 16 weeks (LY 1.0/1.0); or 1.0 mg for 4 weeks, then 2.0 mg for 12 weeks (LY 1.0/2.0).
Report a problemFND-2125118009

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.

Summary

Results from this study12

Version history

Subjects

Publication types

MeSH terms